ASX:MSBBiotechs
Surging Revenue And Late-Stage Trial Progress Might Change The Case For Investing In Mesoblast (ASX:MSB)
Mesoblast Limited has reported full-year 2026 results showing revenue of US$120.25 million versus US$17.2 million a year earlier, with its net loss reduced to US$57.5 million from US$102.14 million and loss per share almost halved.
Alongside RYONCIL’s first full year of commercial sales, Mesoblast has completed patient treatment in a pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, underscoring its dual focus on near-term revenue and late-stage pipeline assets.
Now, we’ll...